References
- Almazroo, O.A., Miah, M.K., Venkataramanan, R. (2017) ‘Drug Metabolism in the Liver.’ Clin Liver Dis, 21(1), pp. 1-20. 10.1016/j.cld.2016.08.001
- Baillie, T.A., Rettie, A.E. (2010) ‘Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.’ Drug Metab Pharmacokinet, 26(1), pp. 15-29. doi: 10.2133/dmpk.dmpk-10-rv-089
- Barras, M., Legg, A. (2017) ‘Drug dosing in obese adults.’ Aust Prescr, 40(5), pp. 189-193. doi: 10.18773/austprescr.2017.053
- Bartkowiak-Wieczorek, J., Wolski, H., Bogacz, A., Kujawski, R., Ożarowski, M., Majchrzycki, M., Seremak-Mrozikiewicz, A. (2015) ‘Gender-specific implications for pharmacology in childbearing age and in postmenopausal women.’ Ginekol Pol, 86(2), pp. 143-149. doi: 10.17772/gp/2002
- Berm, E.J., Gout-Zwart, J.J., Luttjeboer, J., Wilffert, B., Postma, M.J. (2016) ‘A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.’ PLoS One,11(12), e0169065. DOI: 10.1371/journal.pone.0169065
- Berm, E.J., Hak, E., Postma, M., Boshuisen, M., Breuning, L., Brouwers, J.R., Dhondt, T., Jansen, P.A., Kok, R.M., Maring, J.G., van Marum, R., Mulder, H., Voshaar, R.C., Risselada, A.J., Venema, H., Vleugel, L., Wilffert, B. (2015) ‘Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).’ Trials, pp. 16:37. doi: 10.1186/s13063-015-0561-0
- J. G. Blanco, P. L. Harrison, W. E. Evans, M. V Relling, “Human cytochrome P450 maximal activities in pediatric versus adult liver,” Drug Metab. Dispos., 2000; 28 (4), s. 379–382.
- Broly, F., Marez, D., Lo Guidice, J.M., Sabbagh, N., Legrand, M., Boone, P., Meyer, U.A. (1995’ A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.’ Hum Genet, 196(5), pp. 601-3. doi: 10.2147/PGPM.S181334
- Butkiewicz, M., Restrepo, N.A., Haines, J.L., Crawford, D.C. (2016) ‘Drug-drug interaction profiles of medication regimens extracted from a de-identified electronic medical records system.’ AMIA Jt Summits Transl Sci Proc, pp. 33-40. PMID: 27570646
- Doogue, M.P., Polasek, T.M. (2013) ‘The ABCD of clinical pharmacokinetics.’ Ther Adv Drug Saf, 4(1), pp. 5–7. doi: 10.1177/2042098612469335
- Flegal, K.M., Shepherd, J.A., Looker, A.C., Graubard, B.I., Borrud, L.G., Ogden, C.L., Harris, T.B., Everhart, J.E., Schenker, N. (2009) ‘Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults.’ Am J Clin Nutr, 89(2), pp. 500-8. DOI: 10.3945/ajcn.2008.26847
- Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I., Greenblatt, D. J. ‘O- and N-demethylation of venlafaxine in vitro by human liver micro-somes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.’ Neuropsychopharmacology, 20(5), pp. 480–490. doi: 10.1016/S0893-133X(98)00113-4
- Freire, A.C., Basit, A.W., Choudhary, R., Piong, C.W., Merchant, H.A. (2011) ‘Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery.’ International Journal of Pharmaceutics, 1-2, pp. 15-28. doi: 10.1016/j.ijpharm.2011.04.069
- Gaedigk, A., Bradford. L.D., Alander, S.W., Leeder, J.S. (2006) ‘CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.’ Drug Metab Dispos, 34(4), pp. 563-569. doi: 10.1124/dmd.105.008292
- Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., Leeder, J.S. (2016) ‘Prediction of CYP2D6 phenotype from genotype across world populations.’ Genet Med, 19(1), pp. 69-76. doi: 10.1038/gim.2016.80
- Golden, R.N., Nicholas, L. (2000) ‘Antidepressant efficacy of venlafaxine.’ Depress Anxiety, 12 Suppl 1, pp. 45-49. doi: 10.1002/1520-6394(2000)12:1+<;45::AID-DA5>3.0.CO;2-5
- Grasmader, K., Verwohlt, P.L., Rietschel, M. Dragicevic, A., Müller, M., Hiemke, C., Freymann, N., Zobel, A., Maier, W., Rao, M.L (2004) ‘Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.‘ Eur J. Clin. Pharmacol, 60(5), pp. 329–336. doi: 10.1111/j. 1365-2125.2007.03052.x
- Holford, N. (2015) ‘Clinical pharmacology = disease progression + drug action.’ TBr J Clin Pharmacol, 79(1), pp. 8-27. doi: 10.1111/bcp.12170
- http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c3f8268-ef43-d58c-7da6-dd44f-8feb3be.
- http://www.cypalleles.ki.se/5.
- https://cpicpgx.org/resources/term-standardization/.
- https://www.drugbank.ca/drugs/DB00285.
- https://www.pharmvar.org/gene/CYP2D6
- Jiang, F., Kim, H.D., Na, H.S., Lee, S.Y., Seo, D.W., Choi, J.Y., Ha, J.H., Shin, H.J., Kim, YH, Chung MW. (2015) ‘The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.’ Psychopharmacology (Berl), 232(11), pp. 1899-1909. doi: 10.1007/s00213-014-3825-6
- Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269-86. doi: 10.2147/tcrm.s1458
- Johnson E.M., Whyte E., Mulsant B.H., Pollock B.G., Weber, E., Begley, A.E., Reynolds, C.F. (2006) ‘Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.’ Am J Geriatr Psychiatry, 14(9), pp. 796–802. doi: 10.1097/01.JGP.0000204328.50105.b3
- Karki, R., Pandya, D., Elston, R.C., Ferlini, C. (2015) ‘Defining “mutation” and “polymorphism” in the era of personal genomics.’ BMC Med Genomics, 8, pp. 37. doi.org/10.1186/s12920-015-0115-z
- Karlsson, L., Schmitt, U., Josefsson, M., Carlsson, B., Ahlner, J., Bengtsson, F., Kugelberg, F.C., Hiemke, C. (2010) ‘Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking Pglycoprotein.’ Eur Neuropsychopharmacol, 20, pp. 632–640. doi: 10.1016/j.euroneuro.2010.04.004
- Kimura, S., Umeno, M., Skoda, RC., Meyer, UA., Gonzalez, F.J. (1989) ‘The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.’ Am J Hum Genet, 45(6), pp. 889-904. PMID: 2574001; PMCID: PMC1683468.
- Kirchheiner, J., Nickchen, K., Bauer, M. Wong, M.L., Licinio, J., Roots, I., Brockmöller, J. (2004) ‘Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.’ Mol. Psychiatry, 9(5), pp. 442–473. doi: 10.1038/sj.mp.4001494
- Ku, L.C., Smith, P.B. (2014) ‘Dosing in neonates: special considerations in physiology and trial design.’ Pediatr Res. 77(1-1), pp. 2-9. doi: 10.1038/pr.2014.143.
- Lobello, K.W., Preskorn, S.H., Guico-Pabia, C.J., Jiang, Q., Paul, J., Nichols, A.I., Patroneva, A., Ninan, P.T. (2010) ‘Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.’ J Clin Psychiatry, 711, pp. 482–1487. doi: 10.4088/JCP.08m04773blu
- Mackenzie, P.I., Somogyi, A.A., Miners, J.O. (2017) ‘Advances in drug metabolism and pharmacogenetics research in Australia.’ Pharmacol Res, 116, pp. 7-19. doi: 10.1016/j.phrs.2016.12.008
- Magalhães, P., Alves, G., Llerena, A., Falcão, A. (2015) ‘Clinical drug-drug interactions: focus on venlafaxine.’ Drug Metab Pers Ther, 30(1), pp. 3-17. doi: 10.1515/dmdi-2014-0011
- Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.M., Spire, C., Lafitte, J.J., Meyer, U.A., Broly, F. (1997) ‘Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.’ Pharmacogenetics, 7(3): pp. 193-202.doi: 10.1097/00008571-199706000-00004
- McGraw, J., Waller, D. (2012) ‘Cytochrome P450 variations in different ethnic populations.’ Expert Opin Drug Metab Toxicol, 8(3), pp. 371-82. doi: 10.1517/17425255.2012.657626
- Ng, C., Sarris, J., Singh, A. Bousman, C,. Byron, K., Peh, L.H., Smith, D.J., Tan, C.H., Schweitzer, I. (2013) ‘Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.’ Hum. Psychopharmacol, 28(5), pp. 516–522. doi: 10.1002/hup.2340
- Preissner, S.C., Hoffmann, M.F., Preissner, R., Dunkel, M., Gewiess, A., Preissner, S. (2013) ‘Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.’ PLoS One, 8(12):e82562. doi: 10.1371/journal.pone.0082562
- Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.U., Schwab, M., Zanger, U.M. (2000) ‘Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6.’ Pharmacogenetics, 10(7), pp. 577-581. DOI: 10.1097/00008571-200010000-00001
- Roden, D.M., Wilke, R.A., Kroemer, H.K., Stein, C.M. (2011) ‘Pharmacogenomics: the genetics of variable drug responses.’ Circulation, 123(15), pp.1661-1670. doi: 10.1161/CIRCULATIONAHA.109.914820
- Rolla, R., Gramaglia, C., Dalo, V., Ressico, F., Prosperini, P., Vidali, M., Meola, S., Pollarolo, P., Bellomo, G., Torre, E., Zeppegno, P. (2014) ‘An observational study of Venlafaxine and CYP2D6 in clinical practice.’ Clin. Lab, 60(2), pp. 225–231. doi: 10.7754/clin.lab.2013.130141
- Sacristán, J.A., Avendaño-Solá, C. (2015) ‘On heterogeneity of treatment effects and clinical freedom.’ Int J Clin Pract, 69(1), pp. 6-8. doi: 10.1111/ijcp.12537
- Shams, M.E., Arneth, B., Hiemke, C., Dragicevic, A., Müller, M.J., Kaiser, R., Lackner, K., Härtter, S. (2006) ‘CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.’ Journal of clinical pharmacy and therapeutics, 31(5), pp. 493–502. DOI: 10.1111/j.1365-2710.2006.00763.x
- Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K. (2001) ‘dbSNP: the NCBI database of genetic variation.’ Nucleic Acids Res, 1;29(1), pp. 308-311. doi: 10.1093/nar/29.1.308
- Steen, V.M., Molven, A., Aarskog, N.K., Gulbrandsen, A.K. (1995) ‘Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.’ Hum Mol Genet, 4(12), pp. 2251-7. doi: 10.1093/hmg/4.12.2251
- Taranu, A., Colle, R., Gressier, F., El Asmar, K., Becquemont, L., Corruble, E., Verstuyft, C. (2017) ‘Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings’ Pharmacogenomics, 18(7), pp. 639-650. doi: 10.2217/pgs-2017-0003
- Thase, M.E. (2006) ‘Treatment of anxiety disorders with venlafaxine XR.’ Expert Rev Neurother, 6(3), pp. 269-82. doi: 10.1586/14737175.6.3.269
- van den Anker, J., Allegaert, K. (2012) ‘Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach.’ Expert Rev Clin Pharmacol. 5(1), pp. 5-8. doi: 10.1586/ecp.11.65
- Wellington, K., Perry, C.M.T. (2001) ‘Venlafaxine extended-release: a review of its use in the management of major depression.’ CNS Drugs, 15(8), pp. 643-669. doi: 10.2165/00023210-200115080-00007
- Xu, J., Mercury J, Zhang, Z., Xu, F. (2008) ‘Psychological, social and behavioural factors that influence drug efficacy: a noteworthy research subject in clinical pharmacology.’ Br J Clin Pharmacol, 66(6), pp. 901-902. doi: 10.1111/j.1365-2125.2008.03300.x